Synairgen updates on AZD9412

Synairgen (SNG) has confirmed that AstraZeneca has decided to stop the Phase IIa trial for AZD9412 based on an interim analysis, where an overall very low number of reported severe exacerbations could make primary endpoint conclusions difficult.

At 9:04am: (LON:SNG) Synairgen PLC share price was -13p at 21p

Story provided by